Skip to main content
. Author manuscript; available in PMC: 2023 Jul 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2022 Apr 6;113(4):787–795. doi: 10.1016/j.ijrobp.2022.03.033

Table 3.

Summary of HRs for number of +LNs stratified by change point of 5 +LNs for overall survival and disease-free survival and subdistributional HRs for locoregional recurrence and distant metastases

HR/sHR 95% CI P value

Overall survival
 0–5 +LNs 1.21 1.1, 1.34 <.001
 ≥6 +LNs 1.02 1.01, 1.06 <.001
Disease-free survival
 0–5 +LNs 1.19 1.08, 1.30 <.001
 ≥6 +LNs 1.04 1.02, 1.06 <.001
Locoregional recurrence
 0–5 +LNs 1.28 1.10, 1.50 <.001
 ≥6 +LNs 1.00 0.96, 1.04 .98
Distant metastasis
 0–5 +LNs 1.10 1.01, 1.20 .028
 ≥6 +LNs 1.05 1.02, 1.08 .003

Abbreviations: CI = confidence interval; HR = hazard ratio (expressed as 1 unit increment); LN = lymph node; sHR = subdistributional HR.